Related Experiment Videos
Intravitreal triamcinolone for diffuse diabetic macular oedema.
S K Gibran1, A Cullinane, S Jungkim
1Department of Ophthalmology, Cork University Hospital, Cork, Ireland. syedgibran@yahoo.com
Eye (London, England)
|July 16, 2005
Summary
Intravitreal triamcinolone (IVTA) offers a temporary solution for diabetic macular oedema (DME) resistant to laser therapy. This treatment effectively reduces macular thickness and improves vision for about six months.
Area of Science:
- Ophthalmology
- Endocrinology
Background:
- Diabetic macular oedema (DME) is a leading cause of vision loss in diabetic patients.
- Conventional treatments like laser therapy are often insufficient for refractory cases.
Purpose of the Study:
- To assess the efficacy of intravitreal triamcinolone acetonide (IVTA) in treating diffuse diabetic macular oedema (DME) unresponsive to laser therapy.
Main Methods:
- A prospective case series of 38 eyes with refractory DME received a 4 mg intravitreal injection of triamcinolone acetonide.
- Visual acuity (VA) and macular thickness via optical coherence tomography (OCT) were measured at baseline and at 1, 3, and 6 months post-injection.
Main Results:
- Visual acuity improved significantly from baseline (0.905) to 0.605 at 1 month, 0.555 at 3 months, and 0.730 at 6 months.
- Macular thickness decreased from a baseline of 418.7 microm to 276.9 microm at 1 month, 250.6 microm at 3 months, and 308.8 microm at 6 months.
Conclusions:
- Intravitreal triamcinolone acetonide (IVTA) shows potential as a temporary treatment for refractory diabetic macular oedema (DME).
- The treatment effectively reduces macular thickness and enhances visual acuity for approximately six months.
- Further research is needed to determine the long-term safety of IVTA for DME management.